Panacea Venture

Chime Biologics Limited is a Contract Development and Manufacturing Organization (CDMO) based in Wuhan, China, established in 2013. The company specializes in providing a comprehensive range of biopharmaceutical development and manufacturing services, including drug substance and drug product manufacturing, cell line development, and protein science characterization. Chime Biologics also offers technical transfer, regulatory support, and project management services to meet the needs of the biopharmaceutical industry. The organization supports clients through all stages of development, from early drug development to late-stage clinical trials and commercial production, ensuring compliance with cGMP standards. By delivering customer-centric and cost-effective solutions, Chime Biologics aims to enhance access to affordable medicines and improve patient care.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G Protein-Coupled Receptors (GPCRs), which are key drug targets in various diseases. The company specializes in developing treatments for Central Nervous System (CNS) disorders and cancer. Utilizing its proprietary DTect-All technology, Domain Therapeutics identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), which are not discoverable through conventional methods. This innovative approach allows the company to address challenging GPCRs, including orphan and peptidic receptors. Founded in 2001, the company was previously known as Faust Pharmaceuticals SA before rebranding in December 2008.

Day Zero Diagnostics (DZD) is developing a new class of diagnostic that enables a physician to switch from broad spectrum antibiotic therapy to a targeted antibiotic in 5 hours rather than the 2-5 days that it typically takes today. Unlike other molecular diagnostics that can only detect a handful of specific targets, DZD uses the entire genomic sequence and our proprietary Keynome™ algorithm to identify a comprehensive range of bacterial pathogens and their resistance characteristics within hours.

Inmagene Biopharmaceuticals Co. Ltd., founded in 2019 and headquartered in Shanghai, China, is a clinical-stage biotechnology company dedicated to researching and developing novel therapeutics for immunological and inflammatory diseases. The company focuses on creating innovative biomedical drugs to assist patients and healthcare providers in addressing immune-related conditions. Its product pipeline includes IMG-020, a protein drug designed to target IL-17A, developed by integrating Affibody’s protein therapeutics platform for enhanced potency and Albumod technology for extended half-life. Inmagene also has additional offices in Hangzhou and Beijing, China, further supporting its commitment to advancing healthcare solutions in the field of immunology.

Chime Biologics Limited is a Contract Development and Manufacturing Organization (CDMO) based in Wuhan, China, established in 2013. The company specializes in providing a comprehensive range of biopharmaceutical development and manufacturing services, including drug substance and drug product manufacturing, cell line development, and protein science characterization. Chime Biologics also offers technical transfer, regulatory support, and project management services to meet the needs of the biopharmaceutical industry. The organization supports clients through all stages of development, from early drug development to late-stage clinical trials and commercial production, ensuring compliance with cGMP standards. By delivering customer-centric and cost-effective solutions, Chime Biologics aims to enhance access to affordable medicines and improve patient care.

Inmagene Biopharmaceuticals Co. Ltd., founded in 2019 and headquartered in Shanghai, China, is a clinical-stage biotechnology company dedicated to researching and developing novel therapeutics for immunological and inflammatory diseases. The company focuses on creating innovative biomedical drugs to assist patients and healthcare providers in addressing immune-related conditions. Its product pipeline includes IMG-020, a protein drug designed to target IL-17A, developed by integrating Affibody’s protein therapeutics platform for enhanced potency and Albumod technology for extended half-life. Inmagene also has additional offices in Hangzhou and Beijing, China, further supporting its commitment to advancing healthcare solutions in the field of immunology.

XW Laboratories Inc. is a biopharmaceutical company based in Wuhan, China, specializing in the discovery and development of innovative treatments for neurological disorders. Established in 2014, the company has created three distinctive research and development platforms, including Prodrug and Functional Group Switch, which facilitate the rapid identification of new drug candidates while minimizing development costs and time. XW Laboratories aims to enhance patient compliance and reduce toxicity associated with existing medications. In addition to focusing on the domestic market, the company collaborates with international partners to extend its reach in foreign markets, positioning itself at the forefront of medicinal technology in the Asia-Pacific region.

Actym Therapeutics is an immunotherapy company based in Berkeley, California, founded in 2017. The company specializes in developing innovative therapies for cancer treatment, particularly through its proprietary immuno-oncology platform. Actym focuses on engineering immunotherapies that target the tumor microenvironment to enhance the effectiveness of cancer treatments. Its approach includes the development of a novel, tumor-targeting, systemically-delivered STING pathway agonist, which has shown promising anti-tumor activity. By addressing the limitations of existing therapies, Actym aims to provide patients with durable benefits and improved outcomes in the fight against various forms of cancer.

TriArm Therapeutics is a cell therapy company formed by Panacea Venture with R&D operations in Germany, United States and Greater China region. The company focuses on the research and clinical transformation of CD19 CAR-T product using non-viral gene transfer technology, which greatly reduces the cost and time of cell therapy product preparation, enabling better tumor therapy outcome.

Juventas is a developer of innovative immune cell therapeutic drugs aimed at treating malignant hematological neoplasms, including leukemia and lymphoma. The company has had its first investigational new drug application for the cell therapeutic product CNCT19 accepted by the National Medical Products Administration. Juventas is committed to developing a comprehensive product pipeline that focuses on advancing immune cell therapies and accelerating innovation in this field, thereby providing effective treatment options for patients suffering from these serious conditions.

OncXerna Therapeutics offers precision medicine using an innovative RNA-based biomarker platform. OncXerna Therapeutics is aiming to deliver next-generation precision medicine for a larger group of cancer patients by leveraging the company’s deep understanding of how to prospectively identify patients based on the dominant biology of their tumor microenvironments. This allows OncXerna to pair those patients with OncXerna’s clinical-stage therapies with known mechanisms of action that directly address these biologies, to dramatically improve patient outcomes. The company was founded in 2018 and was formerly known as Oncologie.

Tactiva Therapeutics, LLC is an immuno-oncology company focused on developing innovative cancer immunotherapy solutions. Established in 2016 and located in Buffalo, New York, the company specializes in adoptive cell therapy that employs a dual T cell receptor approach. Its platform incorporates engineered CD4 and CD8 T cells, which work together to provide both direct anti-tumor activity and sustained support for T cell-derived effector cells. This strategy aims to enhance the effectiveness of cancer treatments, allowing healthcare professionals to better diagnose and manage life-threatening diseases.

Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing exosome-based therapeutics for the treatment of severe diseases. Founded in 2016, the company leverages its proprietary technology to harness and engineer extracellular vesicles, known as exosomes, for the targeted delivery of nucleic acids and proteins. This innovative approach aims to enhance drug delivery to challenging areas, such as the brain and central nervous system, where conventional therapies often fall short. Evox’s mission is to improve human health by creating novel therapeutics that address significant medical needs, particularly for conditions with limited treatment options. The company has built a comprehensive intellectual property portfolio and is backed by prominent life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based drug delivery.